Astellas Pharma Inc.
14.88 -0.17 (-1.13%)
- Capitalización de mercado
- $26.68B
- Volumen
- 6.92K
- Próxima fecha de resultados
- Oct 29, 2026
Astellas Pharma Inc. (ALPMY): cotización, análisis y datos
Estás viendo el resumen gratuito
Crea una cuenta gratuita para abrir las finanzas, las opciones, las previsiones y el resto de este valor.
Valor intrínseco
Ver planes →Pronóstico del analista
Previsiones bursátiles →$17,40
16.94% Potencial alcista
Últimos resultados
| Reportado | Vs. estimación | Cambio interanual | |
|---|---|---|---|
| Ingresos | — | n/a | n/a |
| EPS | — | n/a | n/a |
Métricas
- Precio de compra
- 14.87
- Ingresos (TTM)
- 2.27T
- Beneficio neto (TTM)
- 365B
- 0.09
- 1.03
- 14.45
- 33.47
- P/B (TTM)
- 2.19
- P/S (TTM)
- 0.01
- Fecha de resultados
- Oct 29, 2026
- Precio de venta
- 14.9
- Volumen
- 6,923
- Volumen medio (20D)
- 141,438
- Abierto
- 14.85
- Anterior Cerrar
- 15.05
- Rango del día
- 14.85 - 14.93
- Rango de 52 semanas
- 10.03 - 17.35
- analista
- n/a
- Precio objetivo
- 17.4 (16.94%)
- Dividendos
- $0.50 (3.29%)
- Fecha ex dividendo
- Mar 31, 2026
Acerca de Astellas Pharma Inc.
Ver perfil →Astellas Pharma Inc. engages in the research, development, manufacture, sale, and supply of pharmaceuticals in Japan and internationally. The company offers XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for acute myeloid leukemia; VYLOY, a treatment for gastric adenocarcinoma and esophagogastric junction adenocarcinoma; and PADCEV, a treatment for patients with metastatic urothelial carcinoma. It also provides VEOZAH, a treatment for vasomotor symptoms associated with menopause; IZERVAY, a treatment for age-related macular degeneration with geographic atrophy; Betanis/Myrabetriq/BETMIGA, a treatment for overactive bladder; and Prograf, an immunosuppressant. It offers its products to oncology, ophthalmology, urology, immunology, and women's health areas. The company was formerly known as Yamanouchi Pharmaceutical Co. Ltd. and changed its name to Astellas Pharma Inc. in April 2005. Astellas Pharma Inc. was founded in 1923 and is headquartered in Chuo, Japan.
Astellas Pharma Inc. engages in the research, development, manufacture, sale, and supply of pharmaceuticals in Japan and internationally. The company offers XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for acute myeloid leukemia; VYLOY, a treatment for gastric adenocarcinoma and esophagogastric junction adenocarcinoma; and PADCEV, a treatment for patients with metastatic urothelial carcinoma. It also provides VEOZAH, a treatment for vasomotor symptoms associated with menopause; IZERVAY, a treatment for age-related macular degeneration with geographic atrophy; Betanis/Myrabetriq/BETMIGA, a treatment for overactive bladder; and Prograf, an immunosuppressant. It offers its products to oncology, ophthalmology, urology, immunology, and women's health areas. The company was formerly known as Yamanouchi Pharmaceutical Co. Ltd. and changed its name to Astellas Pharma Inc. in April 2005. Astellas Pharma Inc. was founded in 1923 and is headquartered in Chuo, Japan.
Industria Drug Manufacturers - General
Sector Healthcare
IPO Fecha Dec 29, 2009
Empleados 14,099
Bolsa de Valores OTC Markets OTCPK
Símbolo bursátil ALPMY
Sitio web https://www.astellas.com